osimertinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 5062 1421373-65-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • osimertinib
  • tagrisso
  • AZD9291
  • AZD-9291
  • AZD 9291
  • osimertinib mesylate
  • osimertinib mesilate
  • AZD9291 mesylate
  • mereletinib
Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR), which binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion) at approximately 9-fold lower concentrations than wild-type. In cultured cells and animal tumor implantation models, osimertinib exhibited anti-tumor activity against NSCLC lines harboring EGFR-mutations (T790M/L858R, L858R, T790M/exon 19 deletion, and exon 19 deletion) and, to a lesser extent, wild-type EGFR amplifications.
  • Molecular weight: 499.62
  • Formula: C28H33N7O2
  • CLOGP: 4.60
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 2
  • TPSA: 87.55
  • ALOGS: -4.35
  • ROTB: 10
  • Status: ONP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
80 mg O

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.906 High 0.88
caco2-efflux Caco-2 efflux ratio (BA/AB) 7.145 High 0.88
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 13.552 10^-6 cm/s High 0.88
dh-clint Dog hepatocyte intrinsic clearance 14.622 uL/min/10^6 cells High 0.88
dppb Dog plasma protein binding (% unbound) 1.730 % High 0.88
fcs-ppb Fetal calf serum protein binding (% unbound) 6.530 % High 0.88
herg hERG pIC50 5.416 pIC50 High 0.88
hh-clint Human hepatocyte intrinsic clearance 2.767 uL/min/10^6 cells High 0.88
hlm-clint Human liver microsomal intrinsic clearance 10.593 uL/min/mg protein High 0.88
hppb Human plasma protein binding (% unbound) 2.380 % High 0.88
kinase-safety-class AAK1,ABL1,ABL2,ACVR2A,ACVR2B,ALK,AURKA,AURKB,AURKC,AXL,BLK,BMX,BTK,CAMK2A,CAMK2B,CAMK2D,CAMK2G,CDK4,CHEK1,CHEK2,CLK2,CLK4,CSF1R,CSK,DDR1,DYRK1A,DYRK1B,EGFR,EIF2AK3,EPHA2,ERBB2,ERBB4,FGFR1,FLT1,FLT3,FYN,GAK,GRK2,IGF1R,INSR,INSRR,IRAK1,IRAK3,IRAK4,ITK,JAK3,KDR,KIT,LCK,LRRK2,LYN,MAP2K1,MAP3K1,MAP3K10,MAP3K11,MAP3K14,MAP3K21,MAP3K7,MAP3K9,MAP4K1,MAP4K2,MAP4K3,MAP4K5,MAPK10,MAPK3,MAPK7,MARK4,MELK,MKNK1,MKNK2,NTRK1,PDGFRB,PDK1,PDK2,PDK4,PLK1,PLK2,PLK3,PLK4,PRKCD,PTK6,RET,RIPK3,SIK2,SIK3,SRC,STK33,SYK,TEK,TNK1,TTK,ULK1,YES1 93
kinase-selectivity-class AAK1,ACVR2B,ALK,BLK,BMX,BTK,CAMK2D,EGFR,ERBB2,ERBB4,GAK,IGF1R,INSR,JAK3,LRRK2,MAP3K9,MAPK7,MINK1,MKNK2,PDK4,PLK2,STK33,TNK1 23
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 8.710 High 0.88
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 9.078 High 0.88
mh-clint Mouse hepatocyte intrinsic clearance 51.286 High 0.88
mppb Mouse plasma protein binding (% unbound) 1.650 High 0.88
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 46.559 High 0.88
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 Moderate 0.68
pppb Pig plasma protein binding (% unbound) 5.610 % High 0.88
rat-kpuu-brain Rat brain Kpuu 0.053 % High 0.88
rh-clint Rat hepatocyte intrinsic clearance 33.574 uL/min/10^6 cells High 0.88
rh-fuinc Rat hepatocyte fraction unbound in incubation 7.630 % High 0.88
rppb Rat plasma protein binding (% unbound) 1.970 % High 0.88
solubility-dd Solubility at pH 7.4 in DMSO 679.204 uM High 0.88

Approvals:

DateAgencyCompanyOrphan
March 28, 2016 PMDA AstraZeneca K.K.
Feb. 2, 2016 EMA AstraZeneca AB
Nov. 13, 2015 FDA ASTRAZENECA PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 2994.57 24.12 1008 15922 105862 90505655
Death 2498.30 24.12 1345 15585 455206 90156311
Drug resistance 1268.92 24.12 390 16540 30059 90581458
Acquired gene mutation 1201.50 24.12 208 16722 1071 90610446
Myelosuppression 1030.60 24.12 384 16546 53207 90558310
Metastases to central nervous system 672.36 24.12 211 16719 17331 90594186
Interstitial lung disease 608.97 24.12 293 16637 76112 90535405
Metastases to meninges 417.46 24.12 104 16826 3631 90607886
EGFR gene mutation 397.66 24.12 67 16863 283 90611234
Paronychia 373.25 24.12 112 16818 7894 90603623
Malignant transformation 329.59 24.12 62 16868 540 90610977
Disease progression 256.22 24.12 221 16709 156394 90455123
Pneumonitis 248.24 24.12 134 16796 44036 90567481
Hepatic function abnormal 231.43 24.12 130 16800 46158 90565359
Metastases to bone 197.31 24.12 96 16834 25409 90586108
Metastases to liver 183.36 24.12 95 16835 28712 90582805
Pleural effusion 182.93 24.12 158 16772 111833 90499684
Metastases to lung 182.89 24.12 79 16851 15912 90595605
Diarrhoea 155.42 24.12 454 16476 938736 89672781
Non-small cell lung cancer 144.26 24.12 47 16883 4334 90607183
Platelet count decreased 136.03 24.12 147 16783 136822 90474695
Dermatitis acneiform 134.56 24.12 49 16881 6305 90605212
Electrocardiogram QT prolonged 130.10 24.12 108 16822 72348 90539169
Cardiac failure 120.23 24.12 124 16806 109372 90502145
Skin toxicity 102.89 24.12 41 16889 6738 90604779
Blood creatine phosphokinase increased 97.27 24.12 67 16863 33956 90577561
Decreased appetite 96.18 24.12 215 16715 376325 90235192
Lymphangiosis carcinomatosa 93.74 24.12 27 16903 1645 90609872
Small cell lung cancer 91.42 24.12 27 16903 1797 90609720
Arthralgia 90.31 24.12 18 16912 778504 89833013
Gene mutation 87.29 24.12 27 16903 2103 90609414
Pain 83.72 24.12 41 16889 996300 89615217
Metastasis 82.43 24.12 34 16896 6103 90605414
Pulmonary embolism 80.13 24.12 110 16820 130710 90480807
Radiation pneumonitis 78.03 24.12 24 16906 1834 90609683
Ejection fraction decreased 75.75 24.12 52 16878 26201 90585316
Deep vein thrombosis 75 24.12 89 16841 91531 90519986
Carcinoembryonic antigen increased 72.49 24.12 24 16906 2326 90609191
Joint swelling 71.74 24.12 6 16924 503294 90108223
Cardiotoxicity 67.99 24.12 36 16894 11353 90600164
Cardiomyopathy 67.88 24.12 44 16886 20162 90591355
BRAF V600E mutation positive 65.75 24.12 11 16919 44 90611473
Neutrophil count decreased 62.73 24.12 72 16858 71460 90540057
Metastases to lymph nodes 61.56 24.12 34 16896 11655 90599862
Thrombocytopenia 61.01 24.12 126 16804 208599 90402918
Nasopharyngitis 60.42 24.12 4 16926 407100 90204417
Malignant pleural effusion 55.92 24.12 21 16909 2943 90608574
Abdominal discomfort 53.28 24.12 12 16918 477316 90134201
Weight increased 51.99 24.12 8 16922 417919 90193598
Swelling 49.96 24.12 9 16921 419049 90192468
Infusion related reaction 49.58 24.12 9 16921 416771 90194746
Sinusitis 46.44 24.12 5 16925 343083 90268434
Headache 46.30 24.12 56 16874 862690 89748827
Cardiac dysfunction 45.18 24.12 19 16911 3578 90607939
Metastases to pleura 44.16 24.12 16 16914 2028 90609489
Non-small cell lung cancer recurrent 44.13 24.12 9 16921 123 90611394
Torsade de pointes 43.62 24.12 30 16900 15152 90596365
Dry skin 43.61 24.12 67 16863 88006 90523511
Cardiac tamponade 42.93 24.12 21 16909 5611 90605906
Respiratory failure 42.51 24.12 78 16852 118340 90493177
Erythema multiforme 41.95 24.12 27 16903 12219 90599298
Hypersensitivity 40.73 24.12 17 16913 454660 90156857
Therapeutic product effect decreased 40.37 24.12 3 16927 277568 90333949
Cerebral infarction 40.29 24.12 36 16894 26560 90584957
Drug hypersensitivity 38.92 24.12 19 16911 463590 90147927
Musculoskeletal stiffness 38.44 24.12 5 16925 296527 90314990
Granulocyte count decreased 37.80 24.12 15 16915 2437 90609080
White blood cell count decreased 37.68 24.12 91 16839 167018 90444499
Hepatic cytolysis 37.53 24.12 37 16893 30879 90580638
Lung adenocarcinoma 37.26 24.12 19 16911 5546 90605971
Pancytopenia 35.57 24.12 73 16857 120190 90491327
Treatment failure 35.20 24.12 7 16923 303921 90307596
Discomfort 34.68 24.12 5 16925 274330 90337187
Neoplasm progression 34.39 24.12 42 16888 44444 90567073
Pericarditis 33.97 24.12 5 16925 270146 90341371
Pulmonary toxicity 33.63 24.12 23 16907 11508 90600009
Hepatotoxicity 33.38 24.12 42 16888 45800 90565717
Mobility decreased 33.05 24.12 4 16926 250730 90360787
Lower respiratory tract infection 33.04 24.12 4 16926 250655 90360862
Maternal exposure during pregnancy 32.98 24.12 13 16917 360050 90251467
Bone marrow failure 32.66 24.12 35 16895 32186 90579331
Lung disorder 32.07 24.12 80 16850 149803 90461714
Peripheral swelling 31.64 24.12 19 16911 413087 90198430
Rash 31.56 24.12 255 16675 795845 89815672
Pneumothorax 31.15 24.12 27 16903 19140 90592377
Contusion 30.79 24.12 5 16925 251211 90360306
Off label use 30.60 24.12 327 16603 1101925 89509592
Skin disorder 30.58 24.12 36 16894 36670 90574847
Impaired healing 30.23 24.12 4 16926 234195 90377322
Subacute cutaneous lupus erythematosus 29.25 24.12 14 16916 3568 90607949
Multiple-drug resistance 28.77 24.12 18 16912 7758 90603759
Anxiety 28.67 24.12 11 16919 309761 90301756
Wheezing 28.59 24.12 5 16925 238075 90373442
Hepatic enzyme increased 28.46 24.12 16 16914 360720 90250797
Cardiac failure acute 28.35 24.12 21 16909 11908 90599609
Non-small cell lung cancer metastatic 27.84 24.12 9 16921 809 90610708
Renal impairment 27.71 24.12 61 16869 105360 90506157
Acute pulmonary oedema 27.69 24.12 19 16911 9561 90601956
Insomnia 27.47 24.12 14 16916 333460 90278057
Hypertension 27.46 24.12 27 16903 457505 90154012
Haematotoxicity 27.42 24.12 21 16909 12514 90599003
Thrombophlebitis migrans 27.28 24.12 7 16923 275 90611242
Blister 27.26 24.12 7 16923 254991 90356526
Pain in extremity 26.56 24.12 27 16903 450502 90161015
Metastases to adrenals 26.26 24.12 9 16921 969 90610548
Eosinophilic pneumonia 26.23 24.12 12 16918 2761 90608756
Drug ineffective 26.17 24.12 152 16778 1384146 89227371
Osteoarthritis 26.10 24.12 3 16927 195727 90415790
Pericardial effusion 25.64 24.12 33 16897 36800 90574717
Migraine 25.18 24.12 3 16927 190389 90421128
Pulmonary alveolar haemorrhage 25.04 24.12 15 16915 5983 90605534
Onychoclasis 24.57 24.12 16 16914 7383 90604134
Ill-defined disorder 24.24 24.12 3 16927 184888 90426629
Immune thrombocytopenia 24.17 24.12 20 16910 13306 90598211
Stress cardiomyopathy 24.13 24.12 20 16910 13335 90598182

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 1403.73 25.54 586 7696 107814 42505239
Death 844.95 25.54 703 7579 470482 42142571
Drug resistance 630.44 25.54 240 8042 34008 42579045
Acquired gene mutation 615.36 25.54 123 8159 1457 42611596
Metastases to central nervous system 427.48 25.54 133 8149 10222 42602831
Myelosuppression 313.29 25.54 154 8128 40307 42572746
Interstitial lung disease 273.81 25.54 177 8105 78285 42534768
EGFR gene mutation 272.46 25.54 46 8236 188 42612865
Metastases to meninges 269.68 25.54 65 8217 1896 42611157
Pneumonitis 142.46 25.54 93 8189 41625 42571428
Hepatic function abnormal 133.68 25.54 97 8185 51470 42561583
Paronychia 123.90 25.54 42 8240 4213 42608840
Malignant transformation 117.05 25.54 29 8253 949 42612104
Metastases to liver 113.90 25.54 58 8224 16268 42596785
Metastases to lung 111.22 25.54 51 8231 11373 42601680
Metastases to bone 107.37 25.54 54 8228 14755 42598298
Disease progression 86.39 25.54 122 8160 143534 42469519
Pleural effusion 68.17 25.54 89 8193 97077 42515976
Dermatitis acneiform 55.42 25.54 28 8254 7711 42605342
Metastases to adrenals 53.25 25.54 16 8266 1086 42611967
Carcinoembryonic antigen increased 47.58 25.54 14 8268 884 42612169
Metastases to lymph nodes 46.79 25.54 23 8259 5975 42607078
BRAF V600E mutation positive 46.74 25.54 8 8274 36 42613017
Malignant pleural effusion 44.24 25.54 16 8266 1939 42611114
Lung disorder 41.77 25.54 49 8233 47874 42565179
Pulmonary embolism 39.86 25.54 78 8204 119534 42493519
Decreased appetite 38.78 25.54 103 8179 193034 42420019
Radiation pneumonitis 34.64 25.54 15 8267 2918 42610135
Rash 34.47 25.54 125 8157 276829 42336224
Pulmonary toxicity 33.72 25.54 21 8261 8634 42604419
Electrocardiogram QT prolonged 33.70 25.54 44 8238 47901 42565152
Metastasis 33.62 25.54 17 8265 4688 42608365
Lymphangiosis carcinomatosa 33.21 25.54 11 8271 1026 42612027
Genital tract inflammation 32.45 25.54 6 8276 45 42613008
Platelet count decreased 29.93 25.54 76 8206 138505 42474548
Drug-induced liver injury 29.85 25.54 37 8245 38236 42574817
Metastases to pleura 29.79 25.54 9 8273 622 42612431
Liver disorder 28.82 25.54 37 8245 39607 42573446
Gene mutation 27.40 25.54 11 8271 1770 42611283

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 3075.96 22.72 1170 19619 173397 110395113
Drug resistance 1755.85 22.72 579 20210 55795 110512715
Acquired gene mutation 1662.44 22.72 308 20481 2446 110566064
Death 1495.13 22.72 1147 19642 697722 109870788
Myelosuppression 1240.20 22.72 514 20275 93826 110474684
Interstitial lung disease 826.04 22.72 438 20351 138896 110429614
Metastases to central nervous system 759.87 22.72 247 20542 22570 110545940
EGFR gene mutation 591.07 22.72 101 20688 469 110568041
Paronychia 430.65 22.72 135 20654 10946 110557564
Malignant transformation 422.16 22.72 89 20700 1436 110567074
Metastases to meninges 393.44 22.72 106 20683 5022 110563488
Hepatic function abnormal 374.23 22.72 224 20565 89071 110479439
Metastases to lung 283.14 22.72 120 20669 22943 110545567
Metastases to liver 272.43 22.72 133 20656 35253 110533257
Pneumonitis 269.75 22.72 172 20617 76359 110492151
Metastases to bone 266.03 22.72 126 20663 31246 110537264
Pleural effusion 227.03 22.72 219 20570 177490 110391020
Dermatitis acneiform 186.09 22.72 75 20714 12620 110555890
Platelet count decreased 176.70 22.72 217 20572 230226 110338284
Electrocardiogram QT prolonged 146.08 22.72 138 20651 108822 110459688
Diarrhoea 145.24 22.72 506 20283 1138999 109429511
Disease progression 132.14 22.72 194 20595 243840 110324670
Lymphangiosis carcinomatosa 125.31 22.72 37 20752 2445 110566065
Decreased appetite 123.00 22.72 274 20515 475572 110092938
Cardiac failure 117.59 22.72 160 20629 187466 110381044
BRAF V600E mutation positive 115.12 22.72 19 20770 68 110568442
Malignant pleural effusion 107.10 22.72 37 20752 4056 110564454
Gene mutation 105.48 22.72 35 20754 3394 110565116
Carcinoembryonic antigen increased 99.72 22.72 32 20757 2792 110565718
Radiation pneumonitis 99.63 22.72 36 20753 4500 110564010
Metastases to lymph nodes 99.43 22.72 51 20738 14981 110553529
Small cell lung cancer 95.09 22.72 32 20757 3240 110565270
Pulmonary embolism 86.37 22.72 149 20640 214325 110354185
Blood creatine phosphokinase increased 81.96 22.72 84 20705 72993 110495517
Arthralgia 77.70 22.72 25 20764 779607 109788903
Ejection fraction decreased 77.30 22.72 63 20726 40817 110527693
Metastases to pleura 75.41 22.72 24 20765 2039 110566471
Skin toxicity 75.11 22.72 39 20750 11744 110556766
Metastasis 72.49 22.72 34 20755 8233 110560277
Pulmonary toxicity 70.30 22.72 43 20746 17703 110550807
Pain 69.96 22.72 47 20742 954908 109613602
Rash 69.09 22.72 321 20468 820643 109747867
Joint swelling 67.26 22.72 4 20785 442841 110125669
Lung disorder 67.18 22.72 121 20668 179926 110388584
Cardiotoxicity 64.57 22.72 40 20749 16841 110551669
Metastases to adrenals 64.22 22.72 20 20769 1583 110566927
Cardiomyopathy 64.09 22.72 52 20737 33473 110535037
Non-small cell lung cancer 61.55 22.72 30 20759 7905 110560605
Deep vein thrombosis 61.35 22.72 101 20688 139786 110428724
Cardiac dysfunction 58.94 22.72 27 20762 6196 110562314
Thrombocytopenia 56.81 22.72 169 20620 348716 110219794
Non-small cell lung cancer recurrent 56.65 22.72 12 20777 198 110568312
Nasopharyngitis 55.77 22.72 5 20784 394356 110174154
Pneumothorax 55.67 22.72 49 20740 35236 110533274
Cerebral infarction 53.48 22.72 57 20732 51781 110516729
Erythema multiforme 49.62 22.72 37 20752 21060 110547450
White blood cell count decreased 49.20 22.72 123 20666 229267 110339243
Drug-induced liver injury 47.74 22.72 83 20706 119984 110448526
Confusional state 44.94 22.72 16 20773 468664 110099846
Respiratory failure 44.65 22.72 114 20675 215218 110353292
Weight increased 44.40 22.72 12 20777 419632 110148878
Cardiac failure acute 43.20 22.72 36 20753 24042 110544468
Torsade de pointes 43.08 22.72 35 20754 22565 110545945
Dry skin 42.25 22.72 74 20715 107579 110460931
Neutrophil count decreased 42.21 22.72 79 20710 120862 110447648
Headache 41.17 22.72 64 20725 882313 109686197
Drug hypersensitivity 41.04 22.72 17 20772 454073 110114437
Granulocyte count decreased 40.03 22.72 18 20771 3956 110564554
Multiple-drug resistance 39.88 22.72 27 20762 13208 110555302
Arthropathy 39.70 22.72 4 20785 287518 110280992
Swelling 39.14 22.72 9 20780 351032 110217478
Liver disorder 38.97 22.72 84 20705 142159 110426351
Hypersensitivity 38.36 22.72 14 20775 403984 110164526
Lung adenocarcinoma 37.51 22.72 23 20766 9508 110559002
Abdominal discomfort 36.81 22.72 14 20775 393844 110174666
Hypertension 36.07 22.72 26 20763 510058 110058452
Pain in extremity 35.54 22.72 24 20765 487094 110081416
Metastases to kidney 34.91 22.72 10 20779 593 110567917
Erythema dyschromicum perstans 34.89 22.72 7 20782 87 110568423
Lower respiratory tract infection 34.57 22.72 3 20786 243103 110325407
Lung carcinoma cell type unspecified recurrent 34.03 22.72 9 20780 396 110568114
Pericardial effusion 33.10 22.72 47 20742 57170 110511340
Therapeutic product effect decreased 32.21 22.72 4 20785 244312 110324198
Left ventricular dysfunction 31.91 22.72 30 20759 23463 110545047
Hypotension 31.76 22.72 31 20758 523818 110044692
Maternal exposure during pregnancy 31.66 22.72 5 20784 254878 110313632
Musculoskeletal stiffness 31.53 22.72 7 20782 279815 110288695
Anxiety 31.04 22.72 13 20776 345065 110223445
TP53 gene mutation 30.97 22.72 7 20782 158 110568352
BRAF gene mutation 30.92 22.72 6 20783 62 110568448
Condition aggravated 30.84 22.72 57 20732 734779 109833731
Hepatotoxicity 29.44 22.72 47 20742 63353 110505157
Infusion related reaction 28.86 22.72 18 20771 381144 110187366
Insomnia 28.75 22.72 16 20773 360574 110207936
Renal impairment 28.48 22.72 89 20700 188356 110380154
Therapy partial responder 28.48 22.72 35 20754 37026 110531484
Bone marrow failure 28.40 22.72 44 20745 57804 110510706
Thrombophlebitis migrans 28.27 22.72 9 20780 765 110567745
HER2 gene amplification 28.08 22.72 4 20785 3 110568507
Subacute cutaneous lupus erythematosus 27.51 22.72 15 20774 4979 110563531
Hepatic enzyme increased 27.43 22.72 13 20776 320879 110247631
Gastrointestinal toxicity 27.22 22.72 20 20769 11128 110557382
Abdominal pain upper 27.10 22.72 16 20773 349095 110219415
Lung opacity 26.43 22.72 20 20769 11632 110556878
Genital tract inflammation 26.03 22.72 6 20783 148 110568362
Contusion 25.97 22.72 6 20783 233355 110335155
Pericarditis 25.68 22.72 5 20784 219109 110349401
Hypertransaminasaemia 25.59 22.72 27 20762 24228 110544282
Asthma 24.91 22.72 8 20781 250283 110318227
Hyperhidrosis 24.85 22.72 3 20786 187295 110381215
Cardiac tamponade 24.75 22.72 19 20770 11288 110557222
Retroperitoneal fibrosis 24.35 22.72 8 20781 752 110567758
Wheezing 23.95 22.72 9 20780 255221 110313289
Neoplasm progression 23.54 22.72 43 20746 64552 110503958
Non-small cell lung cancer stage IV 23.19 22.72 6 20783 242 110568268
Blister 23.11 22.72 7 20782 227369 110341141
Adenosquamous cell carcinoma 22.99 22.72 4 20785 21 110568489
Discomfort 22.95 22.72 6 20783 214701 110353809
Mobility decreased 22.91 22.72 8 20781 237414 110331096
Mouth ulceration 22.78 22.72 36 20753 48102 110520408

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EB04 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
MeSH PA D000092004 Tyrosine Kinase Inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
FDA MoA N0000175082 Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
FDA MoA N0000185506 Cytochrome P450 3A4 Inducers
FDA MoA N0000190113 Breast Cancer Resistance Protein Inhibitors
FDA MoA N0000190114 Cytochrome P450 3A Inhibitors
FDA MoA N0000191266 Cytochrome P450 1A2 Inducers
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:74440 epidermal growth factor receptor antagonist

Related Drugs by ATC class:

L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors 8 drugs
afatinibdacomitiniberlotinibgefitinibicotiniblazertinibmobocertinibolmutinib

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Non-small cell lung cancer, positive for epidermal growth factor receptor expression indication 426964009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.64 acidic
pKa2 7.93 Basic
pKa3 5.6 Basic
pKa4 1.32 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 40MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 9732058 July 25, 2032 ADJUVANT THERAPY AFTER TUMOR RESECTION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER(NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS
EQ 40MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 9732058 July 25, 2032 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS IN COMBINATION WITH PEMETREXED AND PLATINUM-BASED CHEMOTHERAPY
EQ 40MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 9732058 July 25, 2032 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE (STAGE III) NSCLC WHOSE DISEASE HAS NOT PROGRESSED DURING OR FOLLOWING PLATINUM-BASED CHEMORADIATION THERAPY AND WHOSE TUMORS HAVE EGFR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS
EQ 40MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 9732058 July 25, 2032 TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY
EQ 40MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 9732058 July 25, 2032 TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21L858R MUTATIONS
EQ 80MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 9732058 July 25, 2032 ADJUVANT THERAPY AFTER TUMOR RESECTION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER(NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS
EQ 80MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 9732058 July 25, 2032 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS IN COMBINATION WITH PEMETREXED AND PLATINUM-BASED CHEMOTHERAPY
EQ 80MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 9732058 July 25, 2032 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE (STAGE III) NSCLC WHOSE DISEASE HAS NOT PROGRESSED DURING OR FOLLOWING PLATINUM-BASED CHEMORADIATION THERAPY AND WHOSE TUMORS HAVE EGFR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS
EQ 80MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 9732058 July 25, 2032 TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY
EQ 80MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 9732058 July 25, 2032 TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21L858R MUTATIONS
EQ 40MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 8946235 Aug. 8, 2032 ADJUVANT THERAPY AFTER TUMOR RESECTION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER(NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS
EQ 40MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 8946235 Aug. 8, 2032 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS IN COMBINATION WITH PEMETREXED AND PLATINUM-BASED CHEMOTHERAPY
EQ 40MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 8946235 Aug. 8, 2032 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE (STAGE III) NSCLC WHOSE DISEASE HAS NOT PROGRESSED DURING OR FOLLOWING PLATINUM-BASED CHEMORADIATION THERAPY AND WHOSE TUMORS HAVE EGFR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS
EQ 40MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 8946235 Aug. 8, 2032 TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY
EQ 40MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 8946235 Aug. 8, 2032 TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21L858R MUTATIONS
EQ 80MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 8946235 Aug. 8, 2032 ADJUVANT THERAPY AFTER TUMOR RESECTION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER(NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS
EQ 80MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 8946235 Aug. 8, 2032 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS IN COMBINATION WITH PEMETREXED AND PLATINUM-BASED CHEMOTHERAPY
EQ 80MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 8946235 Aug. 8, 2032 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE (STAGE III) NSCLC WHOSE DISEASE HAS NOT PROGRESSED DURING OR FOLLOWING PLATINUM-BASED CHEMORADIATION THERAPY AND WHOSE TUMORS HAVE EGFR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS
EQ 80MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 8946235 Aug. 8, 2032 TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY
EQ 80MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 8946235 Aug. 8, 2032 TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21L858R MUTATIONS
EQ 40MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 10183020 Jan. 2, 2035 ADJUVANT THERAPY AFTER TUMOR RESECTION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER(NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS
EQ 40MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 10183020 Jan. 2, 2035 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS IN COMBINATION WITH PEMETREXED AND PLATINUM-BASED CHEMOTHERAPY
EQ 40MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 10183020 Jan. 2, 2035 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE (STAGE III) NSCLC WHOSE DISEASE HAS NOT PROGRESSED DURING OR FOLLOWING PLATINUM-BASED CHEMORADIATION THERAPY AND WHOSE TUMORS HAVE EGFR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS
EQ 40MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 10183020 Jan. 2, 2035 TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY
EQ 40MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 10183020 Jan. 2, 2035 TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21L858R MUTATIONS
EQ 80MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 10183020 Jan. 2, 2035 ADJUVANT THERAPY AFTER TUMOR RESECTION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER(NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS
EQ 80MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 10183020 Jan. 2, 2035 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS IN COMBINATION WITH PEMETREXED AND PLATINUM-BASED CHEMOTHERAPY
EQ 80MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 10183020 Jan. 2, 2035 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE (STAGE III) NSCLC WHOSE DISEASE HAS NOT PROGRESSED DURING OR FOLLOWING PLATINUM-BASED CHEMORADIATION THERAPY AND WHOSE TUMORS HAVE EGFR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS
EQ 80MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 10183020 Jan. 2, 2035 TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY
EQ 80MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 10183020 Jan. 2, 2035 TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21L858R MUTATIONS
EQ 40MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 12465608 Nov. 26, 2042 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS IN COMBINATION WITH PEMETREXED AND PLATINUM-BASED CHEMOTHERAPY
EQ 80MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL 12465608 Nov. 26, 2042 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS IN COMBINATION WITH PEMETREXED AND PLATINUM-BASED CHEMOTHERAPY

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 40MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL Feb. 16, 2027 IN COMBINATION WITH PEMETREXED AND PLATINUM-BASED CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE EGFR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
EQ 80MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL Feb. 16, 2027 IN COMBINATION WITH PEMETREXED AND PLATINUM-BASED CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE EGFR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
EQ 40MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL Sept. 25, 2027 TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE (STAGE III) NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS NOT PROGRESSED DURING OR FOLLOWING CONCURRENT OR SEQUENTIAL PLATINUM-BASED CHEMORADIATION THERAPY AND WHOSE TUMORS HAVE EGFR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
EQ 80MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL Sept. 25, 2027 TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE (STAGE III) NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS NOT PROGRESSED DURING OR FOLLOWING CONCURRENT OR SEQUENTIAL PLATINUM-BASED CHEMORADIATION THERAPY AND WHOSE TUMORS HAVE EGFR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
EQ 40MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL Dec. 18, 2027 FOR ADJUVANT THERAPY AFTER TUMOR RESECTION IN ADULT PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
EQ 80MG BASE TAGRISSO ASTRAZENECA N208065 Nov. 13, 2015 RX TABLET ORAL Dec. 18, 2027 FOR ADJUVANT THERAPY AFTER TUMOR RESECTION IN ADULT PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Epidermal growth factor receptor Kinase INHIBITOR IC50 7.82 SCIENTIFIC LITERATURE DRUG LABEL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 4.79 CHEMBL
Ribosyldihydronicotinamide dehydrogenase [quinone] Enzyme Kd 5.44 CHEMBL
Receptor tyrosine-protein kinase erbB-2 Kinase IC50 8.32 CHEMBL
Insulin receptor Kinase IC50 6.04 CHEMBL
ALK tyrosine kinase receptor Kinase IC50 6.75 CHEMBL
Activated CDC42 kinase 1 Kinase IC50 7.15 CHEMBL
Tyrosine-protein kinase BTK Kinase Kd 6.28 CHEMBL
Tyrosine-protein kinase JAK3 Kinase IC50 7.45 CHEMBL
Receptor tyrosine-protein kinase erbB-3 Kinase IC50 8.68 CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma Kinase Kd 5.53 CHEMBL
Lysine-specific histone demethylase 1A Enzyme IC50 5.40 CHEMBL
Dipeptidyl peptidase 1 Enzyme IC50 4.48 CHEMBL
Cysteine--tRNA ligase, cytoplasmic Enzyme Kd 7.92 CHEMBL
Tyrosine-protein kinase Tec Kinase Kd 6.49 CHEMBL
Epidermal growth factor receptor Kinase IC50 7.09 CHEMBL

External reference:

IDSource
3C06JJ0Z2O UNII
1421373-66-1 SECONDARY_CAS_RN
4035124 VANDF
C4058811 UMLSCUI
CHEBI:90943 CHEBI
YY3 PDB_CHEM_ID
CHEMBL3353410 ChEMBL_ID
71496458 PUBCHEM_CID
DB09330 DRUGBANK_ID
CHEMBL3545063 ChEMBL_ID
10043 INN_ID
C000596361 MESH_SUPPLEMENTAL_RECORD_UI
7719 IUPHAR_LIGAND_ID
1721559 RXNORM
237132 MMSL
31292 MMSL
d08397 MMSL
016583 NDDF
016584 NDDF
716032009 SNOMEDCT_US
734660003 SNOMEDCT_US
781312009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
TAGRISSO HUMAN PRESCRIPTION DRUG LABEL 1 0310-1248 TABLET, FILM COATED 40 mg ORAL NDA 28 sections
TAGRISSO HUMAN PRESCRIPTION DRUG LABEL 1 0310-1251 TABLET, FILM COATED 80 mg ORAL NDA 28 sections
TAGRISSO HUMAN PRESCRIPTION DRUG LABEL 1 0310-1349 TABLET, FILM COATED 40 mg ORAL NDA 28 sections
TAGRISSO HUMAN PRESCRIPTION DRUG LABEL 1 0310-1350 TABLET, FILM COATED 80 mg ORAL NDA 28 sections